Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WTX212A in Advanced Solid Tumors
NCT07269899Phase 1Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Nov 2025
- Primary completion
- Feb 2027
- Modality
- Antibody-Drug Conjugates (ADCs), Other Engineered Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of WTX212A in solid tumor (2 cohorts), sponsored by Sun Yat-sen University. Primary endpoint: Efficacy of WTX212A monotherapy or WTX212A in combination with radiotherapy at 1 year. Started Nov 2025; status: recruiting.
02
Drugs
WTX212A
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07269899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07269899.